Range Low Price High Price Comment
30 days $3.13 $4.97 Tuesday, 30th Apr 2024 ALDX stock ended at $3.94. This is 2.72% less than the trading day before Monday, 29th Apr 2024. During the day the stock fluctuated 4.33% from a day low at $3.93 to a day high of $4.10.
90 days $2.71 $4.97
52 weeks $1.42 $11.97

Historical Aldeyra Therapeutics prices

Date Open High Low Close Volume
Feb 02, 2016 $4.52 $4.52 $4.52 $4.52 6 500
Feb 01, 2016 $4.80 $4.80 $4.80 $4.80 1 800
Jan 29, 2016 $4.81 $4.81 $4.81 $4.81 5 600
Jan 28, 2016 $4.88 $4.88 $4.88 $4.88 10 200
Jan 27, 2016 $5.05 $5.05 $5.05 $5.05 5 600
Jan 26, 2016 $5.09 $5.09 $5.09 $5.09 24 900
Jan 25, 2016 $5.39 $5.39 $5.39 $5.39 9 500
Jan 22, 2016 $5.50 $5.50 $5.50 $5.50 11 400
Jan 21, 2016 $5.62 $5.62 $5.62 $5.62 19 700
Jan 20, 2016 $5.79 $5.79 $5.79 $5.79 34 200
Jan 19, 2016 $6.16 $6.16 $6.16 $6.16 5 300
Jan 15, 2016 $6.37 $6.37 $6.37 $6.37 32 100
Jan 14, 2016 $6.71 $6.71 $6.71 $6.71 8 200
Jan 13, 2016 $6.55 $6.55 $6.55 $6.55 16 600
Jan 12, 2016 $6.69 $6.69 $6.69 $6.69 31 700
Jan 11, 2016 $6.76 $6.76 $6.76 $6.76 19 400
Jan 08, 2016 $6.75 $6.75 $6.75 $6.75 27 900
Jan 07, 2016 $6.63 $6.63 $6.63 $6.63 8 500
Jan 06, 2016 $6.50 $6.50 $6.50 $6.50 5 500
Jan 05, 2016 $6.68 $6.68 $6.68 $6.68 5 500
Click to get the best stock tips daily for free!

About Aldeyra Therapeutics

Aldeyra Therapeutics Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria... ALDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT